In the battle against Ebola, incentives from governments and healthcare policymakers have been and will continue to be vital...
In the battle against Ebola, incentives from governments and healthcare policymakers have been and will continue to be vital for advancing the current treatment pipeline, by mitigating the risk and up-front costs from pharmaceutical companies, according to an analyst from research and consulting firm GlobalData.
Despite a clear need for novel therapeutic approaches to combat Ebola, the infection has not represented an attractive investment for pharmaceutical companies due to its low incidence and the occurrence of outbreaks in countries that cannot afford expensive medicines.
“These two factors drastically reduce the ability of drug developers to recoup their research and development (R&D) costs,” said Daian Cheng, PhD, an analyst covering infectious diseases. “So far, clinical-stage experimental treatments for Ebola have all been advanced, at least in part, with the financial support of public entities, and the contribution of public resources to R&D has only increased as fears of the virus have spread.”
Cheng notes that the most advanced Ebola pipeline candidate is GlaxoSmithKline’s therapeutic vaccine, cAd3-ZEBOV. This treatment was originally developed jointly by the U.S. National Institute of Allergy and Infectious Diseases and Okairos, which was acquired by GSK in 2013.
“GSK’s vaccine contains a chimpanzee-derived adenovirus vector that carries a single Ebola viral gene and targets the Ebola Zaire strain, which is responsible for the current outbreak,” explained Cheng. “A Phase I study in healthy UK volunteers started in September and the initial manufacturing costs are being supported by a recently-formed international consortium of government bodies and leading research institutions. This is headlined by a joint $4.5 million grant from the Wellcome Trust, the Medical Research Council, and the UK Department for International Development."
The analyst adds that experts are hopeful for data on cAd3-ZEBOV’s safety and dosing in healthy volunteers to be available by the end of this year. Other pharmaceutical companies with promising Ebola treatments that are partially supported by public funding include Johnson & Johnson, Mapp Biopharmaceutical, and NewLink Genetics.
“Ultimately, more partnerships between public entities and pharmaceutical companies are needed to bring to market novel therapies that combat neglected diseases, particularly those which, like Ebola, affect resource-deprived regions of the world,” Cheng concludes.
Read the full release here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.